THERAPEUTIC FOCUS
RESEARCH & DEVELOPMENT
Shareholder Tools
Briefcase Printed Materials Email Alerts Download Center snapshot RSS

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

All Releases
View Summary Amarin to Report Second Quarter 2016 Results and Host Conference Call at 7:30 A.M. ET on August 4, 2016
28 Jul 2016
PDF 13.5 KB Add to Briefcase
View Summary Amarin to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
6 Jul 2016
PDF 11.8 KB Add to Briefcase
View Summary Amarin Appoints Michael W. Kalb Chief Financial Officer
30 Jun 2016
PDF 14.7 KB Add to Briefcase
View Summary Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
11 Jun 2016
PDF 74.7 KB Add to Briefcase
View Summary Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
6 Jun 2016
PDF 69.1 KB Add to Briefcase
View Summary Amarin to Present at the Jefferies 2016 Global Healthcare Conference
1 Jun 2016
PDF 11.7 KB Add to Briefcase
View Summary Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules
31 May 2016
PDF 63.7 KB Add to Briefcase
View Summary Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
20 May 2016
PDF 72.0 KB Add to Briefcase
View Summary Vascepa(R) (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions
11 May 2016
PDF 103.6 KB Add to Briefcase
View Summary Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations
5 May 2016
PDF 99.3 KB Add to Briefcase
View Summary Amarin to Report First Quarter 2016 Results and Host Conference Call on May 5, 2016
28 Apr 2016
PDF 13.2 KB Add to Briefcase
View Summary New Clinical and Pre-Clinical Data Presented at American College of Cardiology Meeting on the Effect of EPA Therapy in Statin-Treated Patients and on Endothelial Function in Exploratory Studies
4 Apr 2016
PDF 72.3 KB Add to Briefcase
View Summary Amarin Reaches Target Enrollment in Cardiovascular Outcomes Study of Vascepa(R) in Patients With Elevated Triglycerides Despite Statin Therapy
31 Mar 2016
PDF 73.0 KB Add to Briefcase
View Summary Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation
9 Mar 2016
PDF 12.2 KB Add to Briefcase
View Summary Amarin's Right to Promote Vascepa(R) Off-Label Affirmed Under First Amendment Litigation Settlement Terms
8 Mar 2016
PDF 69.1 KB Add to Briefcase
View Summary Amarin Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Update on Operations
25 Feb 2016
PDF 102.9 KB Add to Briefcase
View Summary Amarin to Report Fourth Quarter and Full-Year 2015 Results and Host Conference Call on February 25, 2016
18 Feb 2016
PDF 13.4 KB Add to Briefcase
View Summary Request for Continued Stay in Court Proceedings Submitted in Amarin First Amendment Litigation
17 Feb 2016
PDF 12.5 KB Add to Briefcase
View Summary Amarin Appoints Craig B. Granowitz Chief Medical Officer and Names Steven Ketchum Chief Scientific Officer
21 Jan 2016
PDF 71.1 KB Add to Briefcase
View Summary Amarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook
11 Jan 2016
PDF 72.5 KB Add to Briefcase
Showing 1-20 of 259 Page: 1 2 3 4 5 ... 13  Next 20
Add to Briefcase = add release to Briefcase